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Abstract- 
 
We developed a novel detection method for osteopontin (OPN), a new biomarker for prostate 
cancer, by attaching a genetically engineered single chain variable fragment (scFv) protein with 
high binding affinity for OPN to a carbon nanotube field-effect transistor (NTFET). Chemical 
functionalization using diazonium salts is used to covalently attach scFv to NT-FETs, as confirmed 
by atomic force microscopy, while preserving the activity of the biological binding site for OPN. 
Electron transport measurements indicate that functionalized NT-FET may be used to detect the 
binding of OPN to the complementary scFv protein. A concentration-dependent increase in the 
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source-drain current is observed in the regime of clinical significance, with a detection limit of 
approximately 30 fM. The scFv-NT hybrid devices exhibit selectivity for OPN over other control 
proteins. These devices respond to the presence of OPN in a background of concentrated bovine 
serum albumin, without loss of signal. Based on these observations, the detection mechanism is 
attributed to changes in scattering at scFv protein-occupied defect sites on the carbon nanotube 
sidewall. The functionalization procedure described here is expected to be generalizable to any 
antibody containing an accessible amine group, and to result in biosensors appropriate for 
detection of corresponding complementary proteins at fM concentrations. 
 
 
Introduction  
 
Prostate cancer (CaP) is a major public health issue as the most commonly diagnosed cancer and 
second leading cause of cancer deaths among American men1. Detection of early-stage cancer 
often results in successful treatment, with long-term disease-free survival in 60-90% of patients. 
One methodology for early disease detection is biomarker sensing and quantification through 
use of specialized assays. Biomarkers of cancer are molecular or tissue-based signatures of 
disease that provide either diagnostic or prognostic insight into disease etiology and/or 
progression. In the case of CaP, levels of Prostate Specific Antigen (PSA) in patient serum above 
4 ng/mL2 have traditionally been used as a predictive biomarker of disease. However, PSA tests 
are prone to both false positives and false negatives, causing healthy men to undergo 
unnecessary medical procedures as well as men with cancer to go undiagnosed3. This has 
resulted in the utility of PSA as a broad-based screening tool being called into question and 
supports the need for identification of additional biomarkers of CaP. One potential new 
biomarker of CaP is Osteopontin (OPN)4. OPN is a proinflammatory cytokine that regulates bone 
homeostasis through its effects on osteoclast function5. OPN is being investigated both as a 
therapeutic target and as a biomarker for diseases such as arthritis and cancer6, 7. Progression of 
CaP, as well as other cancers, is often associated with metastasis to bone. OPN is thought to play 
a role in the metastatic process and development of metastatic disease correlates with 
increased serum levels of OPN8. Monoclonal antibodies (mAbs) specific for OPN, such as the 
23C3 mAb , represent promising therapeutic and diagnostic agents9, 10. Traditional protein 
detection methods such as ELISA are quite sensitive, but have proven problematic for 
quantification of OPN11. They also require pure samples, lengthy processing times, expertise in 
molecular biology, and could be expensive12. As a result, cost efficient, easy to implement 
immunosensors with comparable or better sensitivity than an ELISA assay would be highly 
desirable. Recently, it was reported that biosensors based on semiconducting nanowire field 
effect transistors (FETs) achieved detection limits for PSA of 5 pM for time domain 
measurement and 150 fM for frequency domain measurements that require more complex 
electronic instrumentation13. This motivated us to explore whether further sensitivity 
enhancements could be achieved through the use of carbon nanotube FETs tightly coupled to 
engineered antibody elements. 
 
Carbon nanotube field effect transistors (NT FETs) provide a unique transduction platform for 
chemical and biomolecular detection14-16. Tailored and specific detection may be accomplished 
by chemically functionalizing the NT FET with a selected antibody to create a hybrid 
nanostructure. Proteins that bind to the hybrid alter the electrical properties of the NT FET via 
several mechanisms17, allowing direct detection as a change in the transistor conduction 
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properties such as threshold voltage or ON state current. Ease of fabrication, well-understood 
carbon surface chemistry, and fast electronic readout make NT FET-based hybrids desirable as 
sensors in either an antibody-antigen detection scheme or as a vapor sensor suitable for more 
complex system architectures characteristic of mammalian olfaction18-21. Large arrays of such 
devices could potentially assist medical diagnosis through simultaneous measurement of 
hundreds of biomarkers using a single small-volume sample22-24.  
 
The binding specificity inherent in mAbs makes them promising agents for use as both targeted 
therapies and as reagents for detecting biomarkers of disease. The murine mAb 23C3 recognizes 
a conserved, linear peptide (43WLNPDP48) within OPN. When administered to animals the 23C3 
immunoglobulin (IgG) induced a therapeutic response in a collagen-induced model of arthritis6 
and led to its humanization (Hu23C3) through a CDR-grafting approach in preparation for 
transition into clinical trial25.  Effective use of targeted therapies for the treatment of cancer and 
other diseases requires paired diagnostic tests to detect the presence or absence of relevant 
biomarkers.  
In this study we have engineered the 23C3 mAb into a single-chain variable fragment (scFv) 
antibody26. ScFv antibodies are comprised of the variable heavy and variable light domains of 
the parental IgG, fused by a short peptide linker, and retain the antigen binding properties of 
the intact IgG. The 23C3 mAb was converted to an scFv in an effort to optimize its structure for 
use on NT FET-based biosensors for the detection of OPN in bodily fluids. Here we found that 
the 23C3 scFv retains its ability to bind OPN, which should allow it to be an effective diagnostic 
surrogate for the Hu23C3 therapeutic antibody. In addition, its small size compared to the 
parental IgG (25kDa and 150 kDa, respectively) is hypothesized to provide advantages over the 
parental IgG when used for production of NT FET-based biosensors. First, scFv can be expressed 
in a bacterial cell system that improves both the speed and cost of goods associated with their 
production as compared to traditional IgGs. Second, the scFv is comprised entirely of the 
antigen-binding domain of the 23C3. Thus, antigen binding by an immobilized scFv is 
hypothesized to bring OPN into closer proximity to the NTFET surface, as compared to what 
would occur with an intact IgG. This should result a greater impact on the electrical properties of 
the device and potentially improve the sensitivity of detection.  
Here we report successful fabrication of NT FETs covalently functionalized with the 23C3 scFv, as 
evidenced by Atomic Force Microscopy and electronic measurements. We observed an antigen-
specific, concentration-dependent sensor response to OPN in buffer with a detection limit 
below 30 fM. The response as a function of concentration was well fit by a model based on the 
Hill-Langmuir equation of equilibrium thermodynamics. 
 
Results and Discussion  
 
NT FET devices were fabricated as described in the Methods section. Briefly, NTs were grown by 
catalytic chemical vapor deposition, and electrical contacts were patterned using a 
photolithographic technique that is optimized to leave a chemically clean NT sidewall27. Pristine 
 4 
sp2-bonded carbon is chemically inert, so steps must be taken to create a defect on which to 
bind proteins (Figure 1). Diazonium salt treatment28 was used to create sp3-bonded sites along 
the nanotube terminated in a carboxylic acid group that was used for further attachment 
chemistry. Raman spectroscopy measurements showed an increase in the ratio of the intensity 
of the D band to the G band after diazonium salt treatment, consistent with the creation of 
covalent bonds to the NT sidewall (see Supplemental Figure 1 in the Supporting Information)29.  
 
 
 
Figure 1: Functionalization scheme for OPN attachment. First, sp3 hybridized sites are created on the nanotube sidewall by 
incubation in a diazonium salt solution. The carboxylic acid group is then activated by EDC and stabilized with NHS. ScFv antibody 
displaces the NHS and forms an amide bond (surface amine-rich lysine residues responsible for this bond are depicted in red), and 
OPN binds preferentially to the scFv in the detection step. The OPN epitope is shown in yellow, and the C-and N-terminuses are in 
orange and green respectively.   
 
The diazonium treatment step was followed by activation and stabilization of the attachment 
site with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride/sulfo- N-
hydroxysuccinimide (EDC/NHS)30. Amine groups associated with lysine residues on scFv proteins 
were expected to displace NHS in the subsequent attachment step to form a covalent bond 
between the scFv and the NT through the phenolic linker. A careful washing procedure was 
employed to minimize scFv binding to the substrate. We expect that the chemical 
functionalization procedure used here for the scFv derived from the 23C3 mAb31 may be 
generalized to broad classes of protein that have a free amine group on their exterior.  
 
Preferential attachment of scFv antibodies to NTs was confirmed by Atomic Force Microscopy 
(AFM) (Fig. 2a). The linear density of attached scFv antibodies was found to be approximately 4-
5 per μm of NT length. Line scans from the AFM images were used to calculate the size of ~180 
features presumed to be scFv antibodies covalently bound to NTs and these data were used to 
form a histogram shown in Fig. 2b. The histogram had its maximum at ~ 2.5 nm, with secondary 
maxima at 5 nm and 7.5 nm. We attribute the primary maximum to attachment of single anti-
OPN scFv molecules, and note that a molecular diameter of 2.5 nm is consistent with their mass 
of 25 kDa; the other maxima are attributed to small scFv aggregates.  
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a)           b) 
 
Figure 2: a) AFM image of scFv antibodies covalently bound to carbon nanotubes, with a typical density of 4-5 attachment sites per 
micrometer of nanotube length. Scale bar is 1 μm. Height scale is 7 nm. b) Histogram of the heights of the white features bound to 
the nanotube in Fig 2a shows a maximum at ~ 2.5 nm, consistent with the expected height of scFv antibodies. Secondary maxima at 
5 nm and 7.5 nm are attributed to small aggregates of scFv antibodies. The total number of features analyzed is 180. 
 
We measured the current-gate voltage  (I-Vg) characteristic of an individual NT FET device after 
each chemical modification to monitor the effect of the chemical functionalization and confirm 
attachment of scFv antibodies (Fig. 3). The most sensitive parameters were the threshold 
voltage where the FET current decreases most sharply and the ON state current carried by the 
device for very negative values of the gate voltage. The diazonium treatment was found to shift 
the turn-off voltage shifted by about -3V, and it reduced the ON state current by 50-90%, 
consistent with increased electron scattering due to generation of defects on the NT sidewall. 
EDC/NHS treatment caused almost no change in the turn-off voltage and a slight decrease in the 
ON state current. ScFv attachment did not change the turn-off voltage and led to a small 
increase in the ON state current, attributed to a reduction in carrier scattering due to the 
presence of the protein compared to that associated with NHS/EDC activation. 
 
To test the sensitivity of the device to exposure to OPN, a 10 µL droplet of PBS buffer containing 
OPN at a known concentration was placed on the sensor and left to incubate for 20 minutes in a 
humid environment, followed by careful washing with DI water. The 20-min incubation time we 
used should allow OPN molecules to diffuse distances of order 300 μm, which we expect is 
sufficient to establish equilibrium between bound and unbound species even at the lowest 
concentration used (1 pg/mL, equal to approximately 30 fM)32, 33.  Each device tested was used 
for a single measurement at a fixed OPN concentration to avoid contamination of the samples. 
The ON state current proved to be very sensitive to the presence of OPN and showed a 
reproducible increase after exposure to OPN (Fig. 3). The response is reported as ΔI/I, the 
percentage increase in ON state current from the scFv functionalized state to the state following 
OPN exposure, which is found to account well for device-to-device resistance variations.  
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a) 
 
b) 
 
Figure 3: a) I-Vg characteristics for a single device after successive functionalization steps. Exposure to OPN at a concentration of 30 
ng/mL (912 pM) caused the ON state current to increase from 29 nA (green curve) to 37 nA (orange curve), an increase of 27%. b) 
Similar data for exposure to OPN at a concentration of 10 pg/mL (304 fM). The ON state current increases from 276 nA to 307 nA, an 
increase of 11%. 
 
The device response varied systematically with OPN concentration as shown in Figure 4. Each 
data point in the plot was averaged data from 5-10 functionalized NT FET devices tested against 
a solution with the same concentration of OPN. To generate a fit to the data, we used a model 
where the device response was comprised of two additive components: an offset response, Z, 
due to incubation in pure buffer with no OPN and a response that is directly proportional to the 
probability that an OPN binding site is occupied. This motivated a fit based on a modified Hill-
Langmuir equation describing ligand-receptor binding in equilibrium34.  
 
 
 
Here c is the OPN concentration, A is the response when all binding sites are occupied, Z is an 
overall offset to account for buffer response, Kd is the dissociation constant, and n is the Hill 
coefficient describing cooperativity of binding. The best fit to the data yielded an offset 
parameter Z = 4%, dissociation constant Kd = 564 pg/mL, maximum response A = 27%, and n = 
.201. The maximum response A and the offset parameter Z were constrained to values that 
were sensible based on the response data and buffer response respectively while n and Kd were 
free to vary. The value of Kd (1.7 x 10
-11 M) obtained by the NT FETs is somewhat lower than Kd 
derived from SPR measurements (Supplemental Figure 1). This difference may be explained by 
the fact that SPR is performed under conditions of buffer flow that preclude re-binding of the 
OPN to the anti-OPN scFv during the dissociation phase measurements. In contrast, the static 
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conditions used with the NT FETs may allow for re-binding, slowing the apparent off-rate and 
resulting in the lower apparent Kd. Interestingly, the values derived on the NT FET are equivalent 
to those predicted for the Hu23C3 mAb derived from ELISA-based methods25. The observed 
value n = .201 indicates negative cooperativity in the binding of OPN to the 23C3 scFv in the 
context of the NT FET biosensor. This could be due to inhibition of multiple OPN molecules 
binding to small aggregates or clusters of scFv due to steric hinderance. Taking into account the 
experimental noise, the inferred detection limit of the scFv-functionalized NT FET devices for 
OPN was 1 pg/mL, or 30 fM. 
 
 
Figure 4: Measured sensor responses over a wide range of concentrations of osteopontin (OPN). The solid line is a fit using a 
modified Hill-Langmuir expression that includes an offset response of 4% due to the buffer itself (see main text). A clear signal is still 
present at OPN concentrations of 1 pg/mL. 
  
The precise mechanism for the observed sensing response remains to be determined. 
Qualitatively, an increase in ON state current implies a reduction in carrier scattering upon OPN 
binding. One possible explanation is that charged sites on the scFv surface are neutralized by 
opposite charges associated with bound OPN, leading to reduced fluctuations in the 
electrostatic potential at the NT surface.  Even in the absence of a quantitative understanding of 
the device response, our results provide strong evidence that the methods used here enabled 
attachment of engineered proteins to a NT FET while maintaining both the high quality 
electronic characteristics of the NT device and the chemical recognition functionality 
characteristic of the protein.  
 
Control experiments were conducted where the scFv-functionalized sensor was incubated in a 
solution of bovine serum albumin (BSA) at high concentration (450 ng/mL) to approximate the 
effect of non-specific proteins that will be present in patient samples. The devices were found to 
give a null response of -0.24 % ± 3.87% (Figure 5), supporting the notion that the scFv antibodies 
bound to the NT sidewall retained their specificity for OPN. In a second test of antigen 
specificity, we functionalized NT FET devices with a different scFv based on the clinically 
validated therapeutic monoclonal antibody trastuzumab35. Trastuzumab, and the derived 4D5 
scFv, binds to the HER2 receptor tyrosine kinase, which is implicated in breast cancer formation 
and progression35. Surface Plasmon Resonance measurements show that the 4D5 scFv binds to 
HER2 with a KD of 1.9 nM
36, equivalent to the binding affinity of 23C3 for OPN. As predicted the 
4D5 scFv exhibits no binding to OPN when analyzed by SPR (Supplemental Figure 3). As detailed 
in Figure 5, 4D5-functionalized devices show no response after exposure to OPN at 100 ng/mL, 
consistent with the SPR data. These control experiments suggest that anti-OPN 23C3 scFv-
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functionalized carbon nanotube sensors exhibit a high level of specificity for OPN, the target 
ligand.  
 
 
Figure 5: Summary of data from control experiments. Devices exposed to neat PBS buffer showed a response of +4%. Exposure to 
bovine serum albumin (BSA) at 450 ng/mL gave a null response. Devices prepared with the anti-HER2 scFv antibody in place of anti-
OPN scFv and exposed to 90 ng/mL OPN also gave a null response. (Inset) Devices prepared with anti-OPN scFv antibodies and 
exposed to a mixture of 90 ng/mL OPN and 450 ng/mL BSA background protein gave a response identical to that expected for 90 
ng/mL OPN in plain buffer.  
 
The specificity of the sensor was further investigated by exposing 23C3 scFv-functionalized 
devices to a mixture of OPN (90 ng/mL) and BSA (450 ng/mL) to partially simulate the 
complexity characteristic of clinical samples. The sensor response of ~ 26% was statistically 
identical to that observed for devices exposed to pure OPN (see Fig. 5). 
  
Conclusions 
 
We demonstrated that biosensor devices comprised of high affinity, engineered antibodies 
coupled to sensitive carbon nanotube transduction elements were capable of detecting prostate 
cancer biomarker at concentrations as low as 1 pg/mL (30 fM), three orders of magnitude lower 
than ELISA immunoassays, the current clinical standard37. The experiments showed an antigen-
specific, concentration-dependent sensor response over a wide range of concentrations (1 
pg/ml – 1 μg/ml) that was in excellent quantitative agreement with a model based on the Hill-
Langmuire equation of equilibrium thermodynamics. Control experiments indicated that the 
anti-OPN scFv retains its highly specific binding characteristics when integrated into the hybrid 
nanostructure: Exposing the sensor to PBS buffer that contained a high concentration of bovine 
serum albumin did not induce a sensing response, and devices functionalized with 4D5 scFv, 
which binds specifically to HER2 and not to OPN, did not produce a sensing response upon 
exposure to OPN. We explored the response of the device to protein mixtures and found that 
the response to OPN in a concentrated protein background was equal to that measured for OPN 
in pure buffer. These observations make us optimistic that this device concept may be 
generalized to many other protein species and is perhaps suitable for translation into a useful 
tool to help diagnose disease and guide its treatment. 
 
Methods  
Device Fabrication: Silicon (p++ doped) wafers with 500 nm thermally grown oxide were 
covered with randomly dispersed iron nitrate catalyst. Carbon nanotubes were grown at 900°C 
via chemical vapor deposition with methane feedstock in an argon/hydrogen reducing 
atmosphere as published previously15. Source and drain electrodes separated by 2.5 μm were 
patterned photolithographically directly on the carbon nanotube network with a bilayer resist 
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process of PMGI and Shipley 1813 followed by metal deposition (5 nm Ti/40nm Pd) in a thermal 
evaporator. Liftoff in acetone and Microposit CD-26 was followed by a brief anneal in Ar/H2 at 
350°C to remove photoresist residues27. Device current-gate voltage (I-VG) characteristics were 
measured under ambient laboratory conditions. Only carbon nanotube transistors with ON/OFF 
ratios greater than 100 and differences between turn-on voltage and turn-off voltage less than 6 
V were used in subsequent measurements.  
 
Expression and Purification of anti-OPN 23C3 scFv: A gene encoding the 23C3 scFv, in a Vh-
linker-Vl orientation, was synthesized based on the publically available amino acid sequence 
(PDB ID: 3CXD) and with a codon usage bias for expression in E. coli. The gene was cloned into 
the pSYN2 expression vector as an NcoI/XhoI fragment and the protein was purified to a level of 
0.2 mg/L of culture from the periplasmic space of TG1 E. coli by sequential Ni-NTA and size 
exclusion chromatography as previously described38. For use as a control, the hu4D5 anti-HER2 
scFv corresponding to the FDA-approved mAb trastauzumab, was synthesized from the 
publically available amino acid sequence in a Vl-linker-Vh orientation as previously described39, 
expressed in TG1 E. coli and purified as described for 23C3 scFv.  
 
Functionalization NTFETs were first functionalized using 4-carboxybenzene diazonium 
tetrafluoroborate that we synthesized according to a published recipe.40 Devices were immersed 
in diazonium salt solution (2.5 mg/mL deionized water) for 1 hour at 40°C to create multiple sp3 
hybridized sites along the nanotube ending in a carboxylic acid group21. After incubation in a 
water bath, devices were rinsed in acetone, methanol and DI water. The carboxylic acid groups 
were then activated and stabilized in a solution of EDC and NHS at concentrations of 6 mg and 
16 mg per 15 mL MES buffer respectively for 15 minutes at room temperature followed by a DI 
water rinse. A solution of scFv antibodies (1 µg/mL) and pH 7.3 was then pipetted onto the 
devices in a humid environment to keep the solution from evaporating, causing NHS-stabilized 
sites to be displaced by scFv protein over an incubation period of one hour.  
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